The heparan sulfate proteoglycan syndecan-1 regulates colon cancer stem cell function via a focal adhesion kinase-Wnt signaling axis.
Sampath Kumar KatakamValeria TriaWey-Cheng SimGeorge W YipStefano MolgoraTheodoros KarnavasEslam A ElghonaimyParide PelucchiEleonora PiscitelliSherif Abdelaziz IbrahimIleana ZucchiRolland ReinboldBurkhard GreveMartin GöttePublished in: The FEBS journal (2020)
In colon cancer, downregulation of the transmembrane heparan sulfate proteoglycan syndecan-1 (Sdc-1) is associated with increased invasiveness, metastasis, and dedifferentiation. As Sdc-1 modulates signaling pathways relevant to stem cell function, we tested the hypothesis that it may regulate a tumor-initiating cell phenotype. Sdc-1 small-interfering RNA knockdown in the human colon cancer cell lines Caco2 and HT-29 resulted in an increased side population (SP), enhanced aldehyde dehydrogenase 1 activity, and higher expression of CD133, LGR5, EPCAM, NANOG, SRY (sex-determining region Y)-box 2, KLF2, and TCF4/TCF7L2. Sdc-1 knockdown enhanced sphere formation, cell viability, Matrigel invasiveness, and epithelial-to-mesenchymal transition-related gene expression. Sdc-1-depleted HT-29 xenograft growth was increased compared to controls. Decreased Sdc-1 expression was associated with an increased activation of β1-integrins, focal adhesion kinase (FAK), and wingless-type (Wnt) signaling. Pharmacological FAK and Wnt inhibition blocked the enhanced stem cell phenotype and invasive growth. Sequential flow cytometric SP enrichment substantially enhanced the stem cell phenotype of Sdc-1-depleted cells, which showed increased resistance to doxorubicin chemotherapy and irradiation. In conclusion, Sdc-1 depletion cooperatively enhances activation of integrins and FAK, which then generates signals for increased invasiveness and cancer stem cell properties. Our findings may provide a novel concept to target a stemness-associated signaling axis as a therapeutic strategy to reduce metastatic spread and cancer recurrence. DATABASES: The GEO accession number of the Affymetrix transcriptomic screening is GSE58751.
Keyphrases
- stem cells
- gene expression
- cancer stem cells
- poor prognosis
- single cell
- cell proliferation
- squamous cell carcinoma
- cell therapy
- transcription factor
- endothelial cells
- small cell lung cancer
- binding protein
- epithelial mesenchymal transition
- induced apoptosis
- papillary thyroid
- tyrosine kinase
- machine learning
- mesenchymal stem cells
- cell adhesion
- deep learning
- big data
- rectal cancer
- protein kinase